Browse studies

Find your next paid study

9 recruiting studies matching your filters

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). …

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System Neoplasms+7 more

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called…

Gastrointestinal Neoplasms

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07218926

Phase 1

A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies

The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 …

Colorectal NeoplasmsGastrointestinal Neoplasms

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT06663319

Phase 1

A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors

This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in p…

Gastrointestinal Neoplasms

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06885034

Phase 1

Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Immune checkpoint inhibitors (ICIs) (also called "immunotherapy") are an effective family of anti-cancer drugs, but they can cause serious side effects. Some e…

Gastrointestinal NeoplasmsGenitourinary CancerThoracic Cancer+2 more

Estimated

~$10 – $6,250

Indiana UniversityNCT07389525

The Canopy Cancer Collective Clinical Registry Protocol

The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol Number of study sites 15 Study Design …

Gastrointestinal NeoplasmsPancreatic CancerColorectal Cancer+4 more

Estimated

~$10 – $1,050

Canopy Cancer Collective, LLCNCT07605702

Observational

Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social functio…

Cancer PainVisceral PainGastrointestinal Neoplasms+76 more

Prospective Study Evaluating the Use of a Novel Through - the- Scope Suturing System as a Dynamic Traction Device During ESD: A Feasibility Study

The goal of this prospective study at Baylor St. Luke's Medical Center is to investigate the the efficacy and safety of using the novel TTS helix tack suture d…

Gastrointestinal Neoplasms

Estimated

~$10 – $750

Baylor College of MedicineNCT06747988

Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions

To evaluate clinical outcome for patients receiving treatment of suspected premalignant and malignant gastrointestinal lesions at Interventional Endoscopy Serv…

Gastrointestinal NeoplasmsBenign Neoplasm of Intestinal Tract

Estimated

~$10 – $750

California Pacific Medical Center Research InstituteNCT01750619